These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 4020140

  • 1. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection.
    Liew FY, Hale C, Howard JG.
    J Immunol; 1985 Sep; 135(3):2095-101. PubMed ID: 4020140
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic immunization against experimental leishmaniasis. V. Mechanism of the anti-protective blocking effect induced by subcutaneous immunization against Leishmania major infection.
    Liew FY, Singleton A, Cillari E, Howard JG.
    J Immunol; 1985 Sep; 135(3):2102-7. PubMed ID: 3160786
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP, Scott CA, Lelchuk R, Gregoriadis G, Liew FY.
    J Immunol; 1989 Jun 15; 142(12):4441-9. PubMed ID: 2786033
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prophylactic immunization against experimental leishmaniasis. III. Protection against fatal Leishmania tropica infection induced by irradiated promastigotes involves Lyt-1+2- T cells that do not mediate cutaneous DTH.
    Liew FY, Howard JG, Hale C.
    J Immunol; 1984 Jan 15; 132(1):456-61. PubMed ID: 6228580
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites.
    Liew FY, Dhaliwal JS.
    J Immunol; 1987 Jun 15; 138(12):4450-6. PubMed ID: 3295049
    [Abstract] [Full Text] [Related]

  • 9. Do sugar residues contribute to the antigenic determinants responsible for protection and/or abolition of protection in Leishmania-infected BALB/c mice?
    Gorczynski RM.
    J Immunol; 1986 Aug 01; 137(3):1010-6. PubMed ID: 2424979
    [Abstract] [Full Text] [Related]

  • 10. Prophylactic treatment of BALB/c mice with cyclosporine A and its analog B-5-49 enhances resistance to Leishmania major.
    Behforouz NC, Wenger CD, Mathison BA.
    J Immunol; 1986 Apr 15; 136(8):3067-75. PubMed ID: 3958489
    [Abstract] [Full Text] [Related]

  • 11. TNF-alpha reverses the disease-exacerbating effect of subcutaneous immunization against murine cutaneous leishmaniasis.
    Liew FY, Li Y, Yang DM, Severn A, Cox FE.
    Immunology; 1991 Oct 15; 74(2):304-9. PubMed ID: 1748478
    [Abstract] [Full Text] [Related]

  • 12. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice.
    Tonui WK, Mbati PA, Anjili CO, Orago AS, Turco SJ, Githure JI, Koech DK.
    East Afr Med J; 2001 Feb 15; 78(2):90-2. PubMed ID: 11682953
    [Abstract] [Full Text] [Related]

  • 13. Non-MHC-linked Th2 cell development induced by soluble protein administration predicts susceptibility to Leishmania major infection.
    Guéry JC, Galbiati F, Smiroldo S, Adorini L.
    J Immunol; 1997 Sep 01; 159(5):2147-53. PubMed ID: 9278301
    [Abstract] [Full Text] [Related]

  • 14. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH, Gentil LG, Dias SS, Fedeli CE, Katz S, Barbiéri CL.
    Vaccine; 2008 Jan 30; 26(5):677-85. PubMed ID: 18160187
    [Abstract] [Full Text] [Related]

  • 15. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection.
    Mitchell GF, Handman E, Spithill TW.
    Aust J Exp Biol Med Sci; 1984 Apr 30; 62 ( Pt 2)():145-53. PubMed ID: 6466205
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells.
    Liew FY, Hale C, Howard JG.
    J Immunol; 1982 Apr 30; 128(4):1917-22. PubMed ID: 6120976
    [Abstract] [Full Text] [Related]

  • 18. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.
    Russell DG, Alexander J.
    J Immunol; 1988 Feb 15; 140(4):1274-9. PubMed ID: 3257774
    [Abstract] [Full Text] [Related]

  • 19. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK, Naskar K, De T.
    Eur J Immunol; 2009 Aug 15; 39(8):2146-60. PubMed ID: 19593771
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy of the vaccination of C57BL/6 mice against infection with different species of Leishmania].
    Monjour L, Ogunkolade W, Pointet P, Vouldoukis I.
    C R Acad Sci III; 1985 Aug 15; 301(18):803-6. PubMed ID: 3936605
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.